Tests a herbal formula for eczema in children against a placebo
Tests a herbal granule formula against placebo for eczema in children aged 4 to 17.
Plain-language title generated from the registry record
Registry title: Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children
Key facts
- Where
- Hong Kong, Hong KongSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 17 years old?
Source: NCT04419584, who can take part
Where in Hong Kong
- The Chinese University of Hong KongHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT04419584
- Record updated
- 30 July 2026
- Original description
The study aims to evaluate the clinical efficacy and safety of the modified Qing-Ying Decoction (mQYD) for the treatment of subacute and chronic atopic dermatitis (AD) in children when compared to the placebo control through examining the clinical symptoms, quality of life, gut microbiome, and Chinese medicine body constitution.Read full original descriptionShow less
A Randomized Placebo-Controlled Clinical Trial of an Innovative Herbal Formula for Atopic Dermatitis in Children: Evaluations of Modified Qing-Ying Decoction on Efficacy and Gut Microbiome
The study aims to evaluate the clinical efficacy and safety of the modified Qing-Ying Decoction (mQYD) for the treatment of subacute and chronic atopic dermatitis (AD) in children when compared to the placebo control through examining the clinical symptoms, quality of life, gut microbiome, and Chinese medicine body constitution.
This is a parallel, randomized, placebo-controlled, double-blind clinical trial. Eligible subjects will be randomly allocated to receive oral mQYD granules or it's placebo granules. Subjects will have 12-week of treatment, and then a 4-week follow-up.
Inclusion: Age of 4 to 17 (Chinese only); With EASI ≥ 10; Subacute and chronic atopic dermatitis presenting with dry, scaly, erythematous papules and plaques; and; Provide written informed consent form (signed by one of their parents).
Exclusion: Having used oral corticosteroids, oral antibiotics, other immunosuppressive or any preparation of oral herbal medicines for the treatment of AD in the past month; History of allergy to Chinese medicines; AD with Yang deficiency in syndrome differentiation, such as pale looking, always feeling cold, fatigue, chronic diarrhea with loose stool, urinary disorders such as urinary difficulty, excessive urination or incontinence; Known overt bacterial infections in the skin; Known severe medical conditions, such as cardiovascular, liver or renal dysfunction or Diabetes Mellitus; Having been diagnosed with scabies, allergic contact dermatitis, seborrheic dermatitis or psoriasis; and; Has taken anti-coagulant or anti-platelet drugs in the past month; Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency; Known pregnancy; Has taken any probiotics, prebiotics in the last month.